Metabolomics-guided mycotoxin management platform for corn wet milling
An integrated platform for managing mycotoxins in corn wet milling using predictive analytics and detoxification strategies. Utilizes LC-MS metabolomics to detect and reduce mycotoxin levels, enhancing safety in food and feed products.
Overview
The metabolomics-guided mycotoxin management platform is an advanced solution designed to enhance the safety and quality of corn wet milling processes. By integrating predictive analytics, rapid screening, and detoxification, this platform addresses the critical need to manage mycotoxin risks effectively. Using LC-MS metabolomics, it measures known and modified mycotoxins across various milling streams, enabling early identification of high-risk lots and targeted detoxification interventions. This approach not only improves product safety but also enhances consistency and value for food and feed applications.
Technical specifications
- Predictive Analytics: Utilizes LC-MS metabolomics to build models that predict toxin enrichment in milling co-products.
- Rapid Screening and Confirmatory Testing: High-risk lots are flagged for rapid screening using advanced analytics.
- Detoxification Strategies: Develops enzymatic or microbial treatments to convert mycotoxins into lower-toxicity products.
- Comprehensive Monitoring: Tracks mycotoxins in raw corn, steep water, protein, fiber, and solubles.
- Scalable and Data-Driven: Designed to integrate seamlessly with existing corn wet milling operations.
Technology readiness level
The platform is currently at Technology Readiness Level 4, indicating that it has been validated in a laboratory setting. Future phases will focus on co-development with industry partners to refine and pilot the solution in actual milling environments.
About University of Pittsburgh
The University of Pittsburgh is a large, comprehensive public research university anchored in an urban innovation corridor with a strong translational focus. Integration with UPMC, a leading academic medical center, enables clinical studies, access to broad patient populations, and co-located clinical–engineering labs that shorten paths from discovery to deployment. A nearby research and technology district, extensive core facilities, and an engineering co-op program give companies entry points for prototyping and talent pipelines. Research is supported by competitive federal funding from agencies such as NIH, NSF, DoD, and DOE. A dedicated technology transfer office provides IP strategy, licensing, startup support, and contracting for industry partners.
delivered to your inbox.